China accepts cluster of complaints under new patent linkage law
The China National Intellectual Property Administration (CNIPA) has accepted its first set of drug patent linkage complaints since the introduction of a new patent law in June 2021. The office confirmed the development in a statement released on October 29.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 July 2023 Certain problems with the patent opposition process need to be addressed in order to protect patent owners, say Alejandro Luna and Luz Elena Elias of Olivares.
9 September 2021 Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.